CASE HUB ARCHIVED–this archived case hub reflects the position at the date of the decision of 9 July 2020; it is no longer maintained. See further, timeline, commentary andrelated cases Case facts Outline CMA Article 101 TFEU/Chapter I and Article 102 TFEU/Chapter II investigation into Aspen’s alleged breach of competition law in relation to the supply of fludrocortisone acetate tablets in the UK. Latest developments On 9 July 2020, the CMA issued its infringement decision, finding that Aspen unlawfully agreed to pay two other firms, Amilco and Tiofarma, to stay out of the UK market for fludrocortisone acetate tablets so that Aspen could maintain its position as the sole UK supplier of fludrocortisone, allowing it to raise prices by 1,800%. The CMA imposed a fine totalling £2.3. In addition, Aspen has made a payment of £8m to the NHS. Parties • Aspen Pharmacare Holdings Ltd, Aspen Global Inc., Apsen Pharma Ireland Ltd, and Aspen Pharma Trading Ltd (together, Aspen: Aspen is a multinational pharmaceutical group with its headquarters in South Africa. It owns a broad portfolio